immunity News and Research

RSS

New mathematical model predicts the spread of COVID-19

Scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory and the University of Illinois Urbana-Champaign (UIUC) have developed a new mathematical model for predicting how COVID-19 spreads.

15 Apr 2021

Population-based study shows the persistence of neutralizing antibodies against coronavirus

It is an open question to what extent protection against reinfection persists after overcoming a SARS-CoV-2 infection.

15 Apr 2021

Modified immune cells may prove a game-changer for patients with late-stage cancers

Modified immune cells that ruthlessly kill cancerous tumors may prove a game-changer for people living with late-stage cancer.

15 Apr 2021

Speed of vaccination is key to reducing COVID-19 spread, says study

Mathematical modeling of the effects of vaccine efficacy and the speed of vaccination show that a lower efficacy vaccine may curb disease transmission similar to that of a higher efficacy vaccine if the speed of immunization is high.

15 Apr 2021

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

A new study published ahead of print in the Clinical Chemistry and Laboratory Medicine (CCLM) journal reports the production of a robust immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the Pfizer-BioNTech BNT162b2 vaccine. The increase in humoral immunity includes elevated Immunoglobulin G (IgG) and Immunoglobulin A (IgA) levels after the second mRNA dose.

14 Apr 2021

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

Researchers in the United States have conducted a pre-clinical study demonstrating the efficacy of two updated versions of the Moderna mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

14 Apr 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

14 Apr 2021

Studies provide insights into characteristics and clinical effect of SARS-CoV-2 B.1.1.7 variant

Two new studies, published in The Lancet Infectious Diseases and The Lancet Public Health, found no evidence that people with the B.1.1.7. variant experience worse symptoms or a heightened risk of developing long COVID compared with those infected with a different COVID-19 strain.

13 Apr 2021

Could cow's milk provide some passive immunity against COVID-19?

Researchers at the Department of Animal Health, University of Cordoba, Córdoba, Spain, speculate that bovine milk consumption – specifically from cows with resistance to bovine coronaviruses – may potentially provide at least some degree of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The article is available to read in full on the Frontiers in Immunology website.

13 Apr 2021

Researchers develop broad-spectrum SARS-CoV-2 RBD-based vaccine

In a recent bioRxiv* preprint, the large team of researchers evaluated a SARS-CoV-2 Spike receptor-binding domain ferritin nanoparticle protein vaccine (RFN) in a nonhuman primate challenge model. This study addresses the need for a next-generation, efficacious vaccine with an increased pan-SARS breadth of coverage.

13 Apr 2021

Measurable antibody response to mRNA COVID-19 vaccine in elderly care home residents

A new preprint research paper posted to the medRxiv* server explores the antibody response to COVID-19 vaccines in elderly residents of nursing homes in the USA. As of March 2021, there have been over 1.4 million infections from SARS-CoV-2 and over 175,000 deaths related to the pandemic among nursing home residents in the country.

13 Apr 2021

High SARS-CoV-2 vaccine effectiveness in California, even with variants

Researchers in the United States and the UK have conducted a study showing that the rollout of vaccines to protect against coronavirus disease 2019 (COVID-19) is proving effective among California's general population.

12 Apr 2021

Nanobody cocktails neutralize SARS-CoV-2 and variants

Researchers report a collection of nanobodies derived from llamas, some of which can work synergistically and work against newer virus variants.

12 Apr 2021

Exercise training may slow breast cancer growth by increasing anti-tumor immune response

Exercise training may slow tumor growth and improve outcomes for females with breast cancer - especially those treated with immunotherapy drugs - by stimulating naturally occurring immune mechanisms, researchers at Massachusetts General Hospital and Harvard Medical School have found.

12 Apr 2021

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

A new preprint, recently released on the bioRxiv* server, explores the impact of a single mutation, the P681H mutation, on the transmissibility of the virus.

12 Apr 2021

Researchers work to develop dual antigen COVID-19 vaccine candidate

A new study has been published on the medRxiv* preprint server, which focuses on the development of a dual-antigen COVID-19' T cell' vaccine. This vaccine is developed based on the expression of both S protein and nucleocapsid (N) protein of SARS-CoV-2, using a next-generation human adenovirus serotype 5 (Ad5) platform.

12 Apr 2021

Could N protein-based COVID-19 vaccines hinder SARS-CoV-2's NK cell inhibition?

Upon SARS-CoV-2 infection, what are the changes occurring on the surface of the host cell? To address this, and a team of researchers undertook a study exploring the natural killer (NK) cells and their role during a SARS-CoV-2 infection.

12 Apr 2021

Lung microbiome predicts COVID-19 disease severity

A new preprint research paper posted to the medRxiv* server found changes to the lung microbiome during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection influence COVID-19 disease severity.

12 Apr 2021

immunity News and Research

New mathematical model predicts the spread of COVID-19

Population-based study shows the persistence of neutralizing antibodies against coronavirus

Modified immune cells may prove a game-changer for patients with late-stage cancers

Speed of vaccination is key to reducing COVID-19 spread, says study

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

SARS-CoV-2 mutations impact T-cell recognition of virus

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

Studies provide insights into characteristics and clinical effect of SARS-CoV-2 B.1.1.7 variant

Could cow's milk provide some passive immunity against COVID-19?

Researchers develop broad-spectrum SARS-CoV-2 RBD-based vaccine

Measurable antibody response to mRNA COVID-19 vaccine in elderly care home residents

High SARS-CoV-2 vaccine effectiveness in California, even with variants

Nanobody cocktails neutralize SARS-CoV-2 and variants

Exercise training may slow breast cancer growth by increasing anti-tumor immune response

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

Researchers work to develop dual antigen COVID-19 vaccine candidate

Could N protein-based COVID-19 vaccines hinder SARS-CoV-2's NK cell inhibition?

Lung microbiome predicts COVID-19 disease severity

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News